Biocon Biologics bags $90-mn contract from Malaysian government to supply human insulin

Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices, and health clinics

April 26, 2022 12:04 pm | Updated 10:18 pm IST - BENGALURU:

Photo used for representation purpose only

Photo used for representation purpose only

Biocon Biologics Limited (BBL), a subsidiary of Biocon on Tuesday said it has bagged a three-year contract valued at $90 million from the Malaysian government for the supply of recombinant human insulin brand Insugen.

Biocon Sdn Bhd., a subsidiary of Biocon Biologics, will manufacture and supply its range of insulins to its partner Duopharma Marketing Sdn. Bhd. (DMktg), a subsidiary of Duopharma Biotech, a pharma & biotech firm in Malaysia.

Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices, and health clinics, as per an official statement.

“This new government contract will enable us to serve over 4,00,000 people with diabetes using recombinant human insulin, helping the government in its journey towards equitable access to diabetes care,” said Susheel Umesh, Chief Commercial Officer, Emerging Markets, Biocon Biologics.

The rh-Insulin formulations, Insugen-R, Insugen-N and Insugen-30/70, are manufactured at Biocon Sdn. Bhd.’s Johor facility and have been approved by the National Pharmaceutical Regulatory Authority (NPRA), Malaysia, said the release.

Biocon Biologics has provided over 2.75 billion doses of rh-Insulin to patients across the world.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.